论文部分内容阅读
作者为进一步评估多发性骨髓瘤(MM)标准化疗与5药联合化疗的疗效,汇集了16所医院92例初治、活动期MM患者。按慢性白血病-骨髓瘤特别研究组(CLMTF)的标准诊断,Durie及Salman法分期。患者按序随机分组,接受下列治疗:(1)VBCMP方案:长春新碱0.03mg/kg(最大量2mg),iv,第1天:卡氮芥0.5mg/kg,iv,第1天;环磷酰胺10mg/kg,iv,第1天;马法兰0.25mg/kg/天,第1-4天;强的松100-150mg/天,第1-4天。或(2)MP方案:马法兰0.25mg/kg/天,第1-4天;强的松100-150mg/天。每隔5周1次,直至1年。按CLMTF标准确定客观的缓解状态。缓解期从M成分产生率下降50%时起算,至M成分减到最低值的两倍为止。有效患者1年后再分为维持组及不维持组。前者每10周以诱导
To further assess the efficacy of standard chemotherapy and 5-drug combination chemotherapy in multiple myeloma (MM), 92 patients with untreated and active MM in 16 hospitals were recruited. According to the chronic leukemia - Myeloma Special Study Group (CLMTF) standard diagnosis, Durie and Salman staging. Patients were randomly assigned to receive the following treatments: (1) VBCMP regimen: vincristine 0.03 mg / kg (maximal 2 mg), iv, day 1: carmustine 0.5 mg / kg, iv, day 1; Phosphamide 10 mg / kg, iv, day 1; melphalan 0.25 mg / kg / day, day 1-4; prednisone 100-150 mg / day, day 1-4. Or (2) MP regimen: melphalan 0.25 mg / kg / day, day 1-4; prednisone 100-150 mg / day. Once every 5 weeks until 1 year. According to CLMTF standard to determine the objective state of remission. The remission period starts from a 50% decrease in the M component production rate until the M component is reduced to twice the minimum. Effective patients were divided into maintenance group and non-maintenance group after one year. The former is induced every 10 weeks